ABOUT US-X-CUTAG THERAPEUTICS (SUZHOU) LIMITED

X-CUTAG

Focusing on unmet medical needs, building an innovative and diversified pipeline portfolio

A global biotech company rooted in China.

We focus on next-generation small-molecule therapeutics through cross-disciplinary integration and iterative innovation. Leveraging the AcuMed Innovations™ intelligent small-molecule R&D platform, we accelerate molecular discovery, integrate a global CRO network, and participate in meaningful clinical programs—delivering more accessible therapeutic options for patients worldwide.

Our History

2017

X-CUTAG THERAPEUTICS INC. was founded in Massachusetts, USA.
2019

Seven US patents were applied and one US patent granted to CTG05.
2020

US patent granted to CTG02.
2021

X-CUTAG THERAPEUTICS (SUZHOU) LIMITED was founded in Suzhou, China.
2023

CTG05 entering the IND phase and applying US patent for CTG06.
2024

CTG05 completed preclinical studies and filed IND application,CTG02、CTG06 entering the IND phase.
2025

CTG05 and CTG06 are set to enter clinical trials. CTG06 has received a U.S. patent application publication.

Our Laboratory

GLP/GCP Certified Laboratory

Honors and Awards